Immediate Hormone Therapy Improves Prostate Cancer Survival

Oncology NEWS InternationalOncology NEWS International Vol 5 No 6
Volume 5
Issue 6

ASCO--In an EORTC study, the combination of radiotherapy and adjuvant hormonal therapy with an LHRH analog has been shown to significantly increase survival in patients with locally advanced prostate cancer, compared with radiotherapy alone.

ASCO--In an EORTC study, the combination of radiotherapy and adjuvanthormonal therapy with an LHRH analog has been shown to significantlyincrease survival in patients with locally advanced prostate cancer,compared with radiotherapy alone.

Michel Bolla, MD, of the University Joseph Fourier Grenoble, representingthe EORTC's Radiotherapy and Genitourinary Tract Cancer CooperativeGroups, presented the data at a scientific session of the AmericanSociety of Clinical Oncology meeting.

Dr. Bolla pointed out that the results, though promising, arepreliminary and need to be confirmed by longer follow-up. Medianfollow-up to date is only 33 months, he said.

In the study, 415 patients with prostate cancer classified asT1,T2 WHO grade 3 or T3,T4 with any histologic grade were randomizedto receive radiotherapy alone or radiotherapy plus the LHRH analoggoserelin (Zoladex) given at the start of radiotherapy and continuedfor 3 years.

Radiotherapy consisted of 5 weeks of treatment to the whole pelvis(up to 50 Gy in 20 fractions), followed by a boost to the prostateand seminal vesicles of 20 Gy for 2 weeks.

Goserelin, 3.6 mg, was given subcutaneously every 4 weeks. Toinhibit a transient rise of testosterone, patients also receivedthe antiandrogen cyproterone acetate for 1 month, starting atleast 1 week before the first goserelin injection.

Over one third of patients (35%) had a high Gleason score (8 to10) and at least 30% had baseline PSA levels 10-fold higher thannormal. Patients who failed when receiving radiotherapy alonewere given the option of receiving delayed hormonal therapy.

Striking Differences

The results showed a striking difference for estimated 5-yearoverall survival between patients receiving combination therapy(78%) and those in the radiotherapy alone arm (56%). Clinicaldisease-free survival was also significantly different--85% forthe hormonal treatment patients vs 44% for the radiotherapy alonegroup.

Clinically defined local control at 5 years was achieved in 95%of those on hormonal therapy, compared with 75% for patients treatedby radiotherapy alone. "The figures speak for themselves,"Dr. Bolla said.

He noted that 95% of patients were able to receive full hormonaltreatment; 21% had adverse reactions, primarily hot flushes, gynecomastia,weakness, and depression, which was likely linked to lack of potency.

The discussant, Dr. Michael Zelefsky, of Memorial Sloan-Kettering,called the study a "landmark--to my knowledge the only trialin the literature using hormonal therapy in combination with radiotherapyto demonstrate a survival benefit." However, he reiteratedDr. Bolla's caution about the preliminary nature of the data andthe short follow-up. "We need to wait longer to see if thesurvival advantage holds."

Dr. Zelefsky cited results of two other randomized trials suggestinga benefit for combined hormonal therapy and external beam radiotherapy--RTOG86-10 and RTOG 86-31--but as yet neither has shown a clear survivaladvantage.

Speaking from the audience, Dr. Mack Roach of the University ofCalifornia, San Francisco, noted that RTOG 86-31 is showing atrend for improvement in survival in patients with high-gradedisease, which would support the European findings.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Related Content